Dr. Andrew Scharenberg, Umoja Biopharma's CEO, discusses the evolution of in vivo CAR-T cell therapeutics and the advantages of this technology. They also cover Umoja's lentiviral vector development and manufacturing facility, and their goals for the future.

Andrew Scharenberg, CEO of Umoja Biopharma, discusses next-gen immunotherapies for cancer, including in vivo CAR T-cell therapy. He talks about indication selection, team building during the pandemic, and the importance of wearing different hats in biotech. The podcast also explores the challenges in manufacturing CAR-T cells, the future of stem cell-derived cell therapies, and managing complexity in drug development.